Navigation Links
Time Magazine Names Agendia Test a Best Invention of 2007
Date:12/4/2007

Important Recognition for Dutch Prognostic Breast Cancer Test MammaPrint(R)

AMSTERDAM, the Netherlands, December 4 /PRNewswire/ -- TIME Magazine has named a new Dutch breast cancer test as one of the best inventions of 2007. This so called "Cancer's Crystal Ball" (MammaPrint(R)) invented and developed by the International company Agendia, gives additional information on the patient's own tumor to support the choice of treatment for that specific patient providing hope to all women who have been diagnosed with breast cancer.

"We are very pleased that we can help millions of women and that TIME has recognized our contribution to the advancement of health care across the globe, most notably in the field of oncology," said Bernhard Sixt, CEO and founder of Agendia. "This honour is a testament to our ongoing commitment to developing state-of-the-art technology for the benefit of cancer patients - not just in the field of breast cancer. In time, I think we'll be able to reach more people than ever before."

The Breast Cancer Test (MammaPrint(R)) measures the activity levels of 70 genes in a sample taken from a woman's surgically-removed breast cancer tumour. It then uses a specific algorithm to determine whether there is a low-risk or high-risk of the cancer spreading to another part of the body. The result can be used to assist physicians in identifying the most suitable treatment and often means that less aggressive therapies can be applied. The Breast Cancer Test is the first test of its kind to have received market clearance by the FDA.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumour gene expression profiling. Agendia was the first company to commercialize such prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centres to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

http://www.agendia.com

* CupPrint (R) is based on a license to the TUO database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
2. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
3. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
4. Inc. Magazine Reveals Its 26th Annual List of Americas 500 Fastest-Growing Private Companies
5. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
6. Allure Magazine Names Remergent(R) DNA Repair Formula Best of Beauty
7. Northern Michigan Regional Health System Named a Working Mother 100 Best Company - 2007 by Working Mother Magazine
8. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
9. Almost Family Named One of Ten Best Newcomers to Forbes Magazine 200 Best Small Companies
10. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
11. National Magazine Ranks Highmark 62nd Among Nations 500 Most Innovative Users of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... announce the ATA 2017 President’s Awards recipients, comprised of organizations and individuals ... delivery. , The ATA 2017 President’s Awards recognize individuals and organizations ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Excellence specializes in pelvic conditions and has helped many women become pregnant upon ... a combination of office-based and simple outpatient evaluations. We can provide the ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... an agile ecosystem and domain expertise for sponsors and CROs to speed ... trial supply management (RTSM) software platform. Bioclinica AGILE RTSM provides ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient ... fewer potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... 20, 2017  Vivify Health, the pioneer and market ... awarded a very significant patent for the advancement of ... care via digital health.  This landmark patent provides the ... further secures Vivify,s position as the leader in remote ... the first company to apply consumer mobile devices, wireless ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
Breaking Medicine Technology: